pre-IPO PHARMA

COMPANY OVERVIEW

Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a disease signal across many relevant genes. Immuneering’s technologies have proven exceptionally rapid and capital-efficient in creating its pipeline. Concurrent with its internal programs, the company provides unparalleled computational biology services to leading pharmaceutical and biotechnology companies.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS


    WEBSITE

    https://immuneering.com


    CAREER WEBSITE

    https://immuneering.com/careers


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jul 29, 2021

    Immuneering Announces Pricing of Upsized Initial Public Offering


    Jul 14, 2021

    Immuneering Expands Board of Directors with Appointment of Ann E. Berman


    Apr 27, 2021

    Immuneering Expands Board of Directors with Addition of Senior Biotechnology Executive Laurie Keating


    Apr 6, 2021

    Immuneering Appoints Biren Amin, M.B.A., as Chief Financial Officer


    Mar 25, 2021

    Immuneering Expands Leadership Team with Appointment of Carolina Garcia Rizo, Ph.D., MBA, as Chief Business Officer


    For More Press Releases


    Google Analytics Alternative